Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


A cell permeable peptide targeting the intracellular loop 2 of endothelin B receptor reduces pulmonary hypertension in a hypoxic rat model.

Green DS, Rupasinghe C, Warburton R, Wilson JL, Sallum CO, Taylor L, Yatawara A, Mierke D, Polgar P, Hill N.

PLoS One. 2013 Nov 27;8(11):e81309. doi: 10.1371/journal.pone.0081309. eCollection 2013.


Enhancing and limiting endothelin-1 signaling with a cell-penetrating peptide mimicking the third intracellular loop of the ETB receptor.

Sallum CO, Wilson JL, Rupasinghe C, Berg E, Yu J, Green DS, Taylor L, Mierke D, Polgar P.

Chem Biol Drug Des. 2012 Sep;80(3):374-81. doi: 10.1111/j.1747-0285.2012.01405.x. Epub 2012 Jun 27.


Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.

Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Louden CS, Hart TK, Elliott JD, Hay DW.

Pulm Pharmacol Ther. 1999;12(1):13-26.


Inhibition of endothelin-1 and hypoxia-induced pulmonary pressor responses in the rat by a novel selective endothelin-A receptor antagonist, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe.

Yan LD, Kong LL, Yong Z, Dong HJ, Chi MG, Pan XF, Zhang C, Liang YJ, Gong ZH, Liu KL.

J Cardiovasc Pharmacol. 2010 Sep;56(3):246-54. doi: 10.1097/FJC.0b013e3181e89f36.


Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension.

Yu J, Taylor L, Wilson J, Comhair S, Erzurum S, Polgar P.

J Cell Physiol. 2013 Feb;228(2):322-9. doi: 10.1002/jcp.24132.


Targeting receptor tyrosine kinases and their downstream signaling with cell-penetrating peptides in human pulmonary artery smooth muscle and endothelial cells.

Yu J, Rupasinghe C, Wilson JL, Taylor L, Rahimi N, Mierke D, Polgar P.

Chem Biol Drug Des. 2015 May;85(5):586-97. doi: 10.1111/cbdd.12446. Epub 2014 Nov 5.


Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.

Liu CP, Dai ZK, Huang CH, Yeh JL, Wu BN, Wu JR, Chen IJ.

Kaohsiung J Med Sci. 2014 Jun;30(6):267-78. doi: 10.1016/j.kjms.2014.02.014. Epub 2014 Apr 30.


Intermedin modulates hypoxic pulmonary vascular remodeling by inhibiting pulmonary artery smooth muscle cell proliferation.

Mao SZ, Fan XF, Xue F, Chen R, Chen XY, Yuan GS, Hu LG, Liu SF, Gong YS.

Pulm Pharmacol Ther. 2014 Feb;27(1):1-9. doi: 10.1016/j.pupt.2013.06.004. Epub 2013 Jun 22.


IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation.

Yang Q, Sun M, Ramchandran R, Raj JU.

Vascul Pharmacol. 2015 Oct;73:20-31. doi: 10.1016/j.vph.2015.04.005. Epub 2015 Apr 25.


The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.

Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S.

J Cardiovasc Pharmacol. 1997 Jun;29(6):713-25.


The endothelin system in pulmonary arterial hypertension.

Galié N, Manes A, Branzi A.

Cardiovasc Res. 2004 Feb 1;61(2):227-37. Review.


Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.

Battistini B, Verreault M, Ayach B, Blouin A, Cernacek P, Jeng AY, Wessale J, Opgenorth T, Tsang J.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S386-9.


Hypoxia-induced reactive oxygen species downregulate ETB receptor-mediated contraction of rat pulmonary arteries.

Wang X, Tong M, Chinta S, Raj JU, Gao Y.

Am J Physiol Lung Cell Mol Physiol. 2006 Mar;290(3):L570-8. Epub 2005 Oct 14.


Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension.

Shatat MA, Tian H, Zhang R, Tandon G, Hale A, Fritz JS, Zhou G, Martínez-González J, Rodríguez C, Champion HC, Jain MK, Hamik A.

Am J Respir Cell Mol Biol. 2014 Mar;50(3):647-53. doi: 10.1165/rcmb.2013-0135OC.


Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.

de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ.

Reprod Toxicol. 2015 Aug 15;56:45-51. doi: 10.1016/j.reprotox.2015.06.048. Epub 2015 Jun 22. Review.


Κ-opioid receptor stimulation improves endothelial function in hypoxic pulmonary hypertension.

Wu Q, Wang HY, Li J, Zhou P, Wang QL, Zhao L, Fan R, Wang YM, Xu XZ, Yi DH, Yu SQ, Pei JM.

PLoS One. 2013 May 7;8(5):e60850. doi: 10.1371/journal.pone.0060850. Print 2013.


Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.

Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Oct;66(4):332-7. doi: 10.1097/FJC.0000000000000283.


The potential of asiaticoside for TGF-β1/Smad signaling inhibition in prevention and progression of hypoxia-induced pulmonary hypertension.

Wang XB, Wang W, Zhu XC, Ye WJ, Cai H, Wu PL, Huang XY, Wang LX.

Life Sci. 2015 Sep 15;137:56-64. doi: 10.1016/j.lfs.2015.07.016. Epub 2015 Jul 22.


Quercetin reverses experimental pulmonary arterial hypertension by modulating the TrkA pathway.

He Y, Cao X, Liu X, Li X, Xu Y, Liu J, Shi J.

Exp Cell Res. 2015 Nov 15;339(1):122-34. doi: 10.1016/j.yexcr.2015.10.013. Epub 2015 Oct 21.


Supplemental Content

Support Center